Neuroscience
The data showed mixed end results, but the diagnostics involved in treating Alzheimer’s were the star of the conference.
With the International Conference on Alzheimer’s and Parkinson’s Diseases still ongoing, there has been increased news about Alzheimer’s. Here’s a look at just a few of the latest stories.
Biogen reported new data from a long-term extension phase of the Phase III clinical studies of Aduhelm (aducanumab) for Alzheimer’s disease.
The Media and Innovation Lab at the University of Miami is developing digital twins of patients in an effort to bring robust healthcare to underserved communities.
Araclon Biotech of Spain revealed positive data from the first part of a phase II trial for its immunotherapeutic vaccine to prevent Alzheimer’s disease- ABvac40.
An investigation into the estrogen-brain link will be led by the Tulane Brain Institute’s multidisciplinary team, whose expertise spans across the pharmacology, physiology and molecular biology industries.
On Wednesday, Breakthrough Properties announced the launch of StudioLabs, a turnkey, flexible lab and office solution that has been developed for hyper-growth life sciences companies.
This target date is the latest development in a long series of setbacks that Acadia - and other pharma companies - have experienced getting Alzheimer’s treatments approved.
After months of speculation about looming layoffs, Biogen is handing out pink slips in order to save about $500 million.
APOE4 is associated with an increased risk of Alzheimer’s disease. A European consortium coordinated by the University of Geneva believes they have identified at least one mechanism of action.
PRESS RELEASES